QUIT Stock Forecast: Achieve Life Sciences, Inc. Price Predictions for 2026-2027
The 11 Wall Street analysts covering Achieve Life Sciences, Inc. hold a median 12-month price target of $13 — +133.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 44 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Achieve Life Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (80): The shares have been drifting up relative to others.
Issuance (13): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
QUIT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on QUIT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +133.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 Sept 2026 | Stifel | Initiates | Buy | $18 |
| 13 Aug 2026 | Morgan Stanley | Initiates | Overweight | $13 |
| 22 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $12 |
| 21 Apr 2026 | Canaccord Genuity | Initiates | Buy | — |
| 16 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Nov 2025 | Citizens | Initiates | Market Outperform | — |
| 21 Aug 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 14 Nov 2024 | Rodman & Renshaw | Initiates | Buy | — |
| 27 Sept 2024 | Raymond James | Initiates | Strong Buy | $20 |
| 15 Aug 2024 | Oppenheimer | Reiterates | Outperform | — |
| 13 May 2024 | Oppenheimer | Maintains | Outperform | — |
| 17 Apr 2024 | JonesTrading | Initiates | Buy | — |
| 1 Apr 2024 | Oppenheimer | Reiterates | Outperform | — |
| 5 Mar 2024 | Lake Street | Maintains | Buy | — |
| 12 Dec 2023 | Oppenheimer | Maintains | Outperform | — |
| 1 June 2023 | Lake Street | Maintains | Buy | — |
| 31 May 2023 | Lake Street | Maintains | Buy | — |
| 10 May 2023 | Lake Street | Maintains | Buy | — |
| 17 Mar 2023 | Oppenheimer | Reiterates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for QUIT.
This page is one stock. Monday covers all of them.
QUIT appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
QUIT vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Achieve Life Sciences, Inc. returned +43.3% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
QUIT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- −31.0%
- Dividend yield
- —
Higher than 14% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Achieve Life Sciences, Inc. has a market value of $573.2M and an enterprise value of $522.3M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$114.0M.
Diluted earnings per share, trailing twelve months: −$1.55.
Free cash flow in the twelve months to 30 June 2026: −$47.2M.
Achieve Life Sciences, Inc. employs 28 people.
Data provided by Twelve Data
QUIT and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at QUIT’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Achieve Life Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about QUIT
What is the QUIT stock price forecast for 2026-2027?
The 11 Wall Street analysts covering Achieve Life Sciences, Inc. have a median 12-month price target of $13, with estimates ranging from $10 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is QUIT stock a buy right now?
Of the 11 analysts covering Achieve Life Sciences, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Achieve Life Sciences, Inc. 44 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank QUIT?
As at 21 Nov 2026, Achieve Life Sciences, Inc. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (80 of 100).
Will QUIT stock go up?
No one can know that. What the data says: the median 12-month target from 11 analysts implies +133.8% from the last close, and Ticker Nerd's factor model ranks Achieve Life Sciences, Inc. 44 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the QUIT stock forecast for 2030?
No analyst covering Achieve Life Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QUIT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $21 over the next 12 months.
How has QUIT stock performed over the past year?
Achieve Life Sciences, Inc. returned +43.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Achieve Life Sciences, Inc. do?
Achieve Life Sciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing treatments for nicotine dependence. Its primary product is cytisinicline, an investigational therapy derived from the naturally occurring alkaloid cytisine.
About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing treatments for nicotine dependence. Its primary product is cytisinicline, an investigational therapy derived from the naturally occurring alkaloid cytisine. The compound is designed to interact with nicotinic acetylcholine receptors in the brain, helping reduce nicotine cravings and withdrawal symptoms for people seeking to stop smoking or vaping. The company’s activities span late-stage clinical development, regulatory preparation, and commercialization efforts across markets including the United States, Canada, and the United Kingdom. Achieve Life Sciences, Inc. operates within the pharmaceutical and smoking-cessation sectors, addressing a major public-health need associated with tobacco and nicotine use. Its focused product portfolio and emphasis on a single therapeutic area distinguish it from diversified drug manufacturers, while its work supports the development of prescription-based options for nicotine independence.
CEO Dr. Andrew D. Goldberg M.D. · 28 employees · United States · https://www.achievelifesciences.com